Centurion Pharma began its journey in 1949 and now, in cooperation with important organizations of the world, it imports products directed towards use in treatment of rarely encountered diseases of Turkey, as well as biological, biotechnological products, hospital instruments and vaccines which are today’s modern treatment alternatives.
Centurion Pharma, which believes that every patient deserves modern treatment alternatives and a high quality of life, established its R&D department in 2011 and ever since, it has taken a giant step in order for specific and special products to be manufactured in our country.
Centurion Pharma embraces respect for the human being, nature and the homeland as its core values and, as one of the leading firms in the sector with its flexible, creative, competitive and job-oriented structure, it acts responsibly and will continue to aim for higher targets in the future.
Contact Details
Adress : Hoşsohbet sk. No:6 Balmumcu/Beşiktaş/İstanbul
Pho : +90 212 275 07 08
Pho : +90 212 275 07 09
Fax : +90 212 274 61 49
Mail : info@centurion.com.tr
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
